Inceptua Group acquires SupplyRx to strengthen clinical trial pharmacy services

The acquisition is expected to strengthen Inceptua's Pharmacy Model capabilities in North America

Lilly’s Taltz-Zepbound combination delivers stronger one-year results in psoriatic disease & obesity trials

The results build on statistically superior outcomes reported at Week 36, when the combination outperformed Taltz alone on key disease and metabolic measures

HaemaLogiX treats first patient with KMCAR T-cell therapy in Phase I multiple myeloma trial

The Australian biotech player is evaluating the therapy in patients with relapsed or refractory kappa-restricted multiple myeloma

Zydus’ Saroglitazar Mg clears key hurdle in global MASH trial

EVIDENCES-X trial met its primary endpoint, with a 26.5% treatment difference in MASH resolution without worsening of fibrosis

Roche’s Vabysmo delivers sustained vision gains in two-year PCV data

The treatment also enabled longer dosing intervals for many patients

Tezspire delivers positive Phase III results in eosinophilic esophagitis

The trial’s two co-primary endpoints assessed histologic remission and the frequency and severity of dysphagia

AbbVie seeks EU nod for subcutaneous SKYRIZI induction in Crohn’s disease

The study’s co-primary endpoints were clinical remission, defined as a Crohn’s Disease Activity Index (CDAI) score below 150

Creative Medical completes Olastrocel trial enrollment as it sets sights on FDA Phase 3 path

Kynexis raises €40 million to push cognition drug toward late-stage trials

Kynexis has completed enrollment in the Phase 2 study and expects to report topline results by the end of 2026

Novo Nordisk begins late-stage trial to test lower-dose oral Wegovy for weight loss

The 60-week, randomised Phase III study will enrol 450 adults with a BMI of 30 or above, or 27 or above with at least one obesity-related health condition

AstraZeneca’s Enhertu delivers first-line win in HER2-mutant lung cancer trial

The trial will continue to assess secondary endpoints, including overall survival

AstraZeneca halts Phase III lung cancer trial after drug unlikely to meet key endpoints

The decision follows a planned review by the Independent Data Monitoring Committee

PhenoNet gets FDA green light for Phase 3 Alzheimer’s trial

The trial will evaluate PHENOGENE-1A in both APOE4 carriers and non-carriers

Indraprastha Apollo launches clinical trial for non-invasive tremor treatment

Delhi hospital begins evaluating ZAP-X Gyroscopic Radiosurgery System for severe essential tremor, offering a frame-free alternative for patients unresponsive to medication

Obsidian advances melanoma cell therapy toward potential FDA filing

With first patient in registration-ready trial

BostonSight and LVPEI launch clinical trial to assess mental health impact of PROSE and SCLERAL lenses

BostonSight PROSE and BostonSight SCLERAL are FDA-cleared medical devices used as part of customized medical treatment

Allergan Aesthetics’ BOTOX Cosmetic moves closer to new jawline treatment approval

This submission builds on the depth and versatility of BOTOX Cosmetic and reflects our continued investment in advancing aesthetic medicine

Moleculin reports promising preliminary phase II/III data for leukaemia drug Annamycin

Blinded interim analysis shows 37% composite remission rate for drug that aims to treat relapsed or refractory acute myeloid leukaemia

Novo Nordisk's Phase 3 ZEUS trial misses cardiovascular endpoint for Ziltivekimab

The study reported a hazard ratio of 0.99 versus placebo

Pfizer’s LITFULO clears two Phase 3 vitiligo trials paving way for global regulatory filings

The trials represent the largest Phase 3 clinical program to date evaluating an oral systemic therapy for the disease